Pharmaceutical / Drug Definition :
Stimulates intracellular adenylate cyclase, an enzyme that catalyzes conversion of adenosine triphosphate to cyclic-3', 5'-adenosine monophosphate (cAMP). Increased cAMP levels relax bronchial smooth muscle and inhibit release of mediators of immediate hypersensitivity (especially from mast cells).
In the United States, Salmeterol Xinafoate is regulated by the U.S. Food and Drug Administration (FDA). FDA has specific requirements regarding the registration and listing of Salmeterol Xinafoate.
FDA Label Requirements and Exceptions
FDA Import Information
Salmeterol Xinafoate (Salmeterol Xinafoate Entry Refusal)
General U.S. Food and Drug Administration Guidelines for:
- Manufacturers Salmeterol Xinafoate (Salmeterol Xinafoate Suppliers)
- Processors Salmeterol Xinafoate
- Repackers Salmeterol Xinafoate
- Relabelers Salmeterol Xinafoate
- Exporters Salmeterol Xinafoate
- Importers Salmeterol Xinafoate
For more information about Salmeterol Xinafoate, simply click below:
U.S. FDA Regulations:
U.S. FDA Regulation: 21 C.F.R. Part 207
Registrar Corp assists businesses with U.S. FDA compliance. Certificates of Registration issued by Registrar Corp provide confirmation to industry that you are fulfilling U.S. FDA registration requirements. U.S. FDA does not issue or recognize Certificates of Registration. Registrar Corp is not affiliated with the U.S. Food and Drug Administration.